Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMAOTCMKTS:CLXPFNASDAQ:PCVXOTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$20.81-3.7%$20.88$10.21▼$25.67$4.97B0.473.67 million shs2.76 million shsCLXPFCybin$8.65-0.7%$7.10$0.49▼$3.38$1.29BN/A551,962 shs190,135 shsPCVXVaxcyte$34.56+0.3%$32.58$27.66▼$121.06$4.46B1.21.44 million shs1.19 million shsZLDPFZealand Pharma A/S$74.13$66.46$57.97▼$141.74$5.26B0.74917 shs80 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-1.23%+8.32%+8.65%+17.20%+100.37%CLXPFCybin-2.79%+1.52%+31.57%+19.32%+2,771.74%PCVXVaxcyte-2.77%-0.98%+14.68%-53.66%-53.39%ZLDPFZealand Pharma A/S0.00%+4.24%+16.29%-12.28%-17.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.1843 of 5 stars2.61.00.00.02.12.51.9CLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.8154 of 5 stars4.62.00.00.02.11.70.0ZLDPFZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2516.53% UpsideCLXPFCybin 0.00N/AN/AN/APCVXVaxcyte 3.10Buy$136.50294.97% UpsideZLDPFZealand Pharma A/S 3.67Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CLXPF, ZLDPF, ADMA, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/31/2025PCVXVaxcyteEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.81$0.07 per share311.70$0.60 per share34.68CLXPFCybin$680K1,890.25N/AN/A$0.44 per share19.66PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/AZLDPFZealand Pharma A/S$9.09M579.17N/AN/A$4.49 per share16.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8574.3230.16N/A17.80%53.20%26.07%8/6/2025 (Estimated)CLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/APCVXVaxcyte-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%8/5/2025 (Estimated)ZLDPFZealand Pharma A/S-$102.18M-$2.49N/AN/AN/A-1,725.03%-15.24%-13.77%8/21/2025 (Estimated)Latest CLXPF, ZLDPF, ADMA, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/8/2025Q1 2025ZLDPFZealand Pharma A/S-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26CLXPFCybinN/A13.5713.57PCVXVaxcyteN/A17.8817.88ZLDPFZealand Pharma A/S0.0335.4935.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%CLXPFCybin0.01%PCVXVaxcyte96.78%ZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%CLXPFCybinN/APCVXVaxcyte3.10%ZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableCLXPFCybin50148.60 millionN/ANot OptionablePCVXVaxcyte160129.00 million120.77 millionOptionableZLDPFZealand Pharma A/S34071.02 millionN/ANot OptionableCLXPF, ZLDPF, ADMA, and PCVX HeadlinesRecent News About These CompaniesAnalysts Set Expectations for OTCMKTS:ZLDPF FY2025 EarningsJune 13 at 2:17 AM | americanbankingnews.comCantor Fitzgerald Comments on OTCMKTS:ZLDPF FY2026 EarningsJune 12 at 8:49 AM | marketbeat.comFY2025 EPS Forecast for Zealand Pharma A/S Raised by AnalystJune 11 at 8:26 AM | marketbeat.comCantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2025 EarningsMay 24, 2025 | marketbeat.comZealand CEO: Oral weight loss meds are not the future for treating obesityMay 15, 2025 | seekingalpha.comZealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...May 9, 2025 | finance.yahoo.comInside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambitMay 2, 2025 | cnbc.comZealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?May 1, 2025 | zacks.comZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as Chief Scientific OfficerApril 23, 2025 | contractpharma.comZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comZealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025April 19, 2025 | finance.yahoo.comZealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With RocheApril 11, 2025 | wsj.comGubra’s obesity drug trial success weighs on Zealand Pharma stockApril 2, 2025 | investing.comZealand Pharma upgraded to Overweight from Equal Weight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)March 18, 2025 | markets.businessinsider.comRoche-Zealand deal is the latest to boost obesity spaceMarch 12, 2025 | msn.comZealand Pharma's new drug petrelintide will help people lose weight: CEOMarch 12, 2025 | youtube.comRoche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidateMarch 12, 2025 | cnbc.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLXPF, ZLDPF, ADMA, and PCVX Company DescriptionsADMA Biologics NASDAQ:ADMA$20.81 -0.79 (-3.66%) Closing price 04:00 PM EasternExtended Trading$20.90 +0.09 (+0.43%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Cybin OTCMKTS:CLXPF$8.65 -0.06 (-0.69%) As of 06/12/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.Vaxcyte NASDAQ:PCVX$34.56 +0.10 (+0.29%) Closing price 04:00 PM EasternExtended Trading$34.58 +0.02 (+0.06%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Zealand Pharma A/S OTCMKTS:ZLDPF$74.13 0.00 (0.00%) As of 06/12/2025Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
